Paper Details

  1. Home
  2. Paper Details

Itraconazole in neutropenic patients.

Author: van't WoutJ W

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

A study of 32 neutropenic patients with fungal infections compared the effectiveness of itraconazole and amphotericin B. Both treatments were effective against Candida infections, with 9 out of 16 patients responding to amphotericin B and 10 out of 16 responding to itraconazole. Itraconazole was more effective against Aspergillus infections, with 6 out of 8 patients responding compared to 2 out of 5 on amphotericin B. While amphotericin B treatment was associated with three deaths from Aspergillus infections, no deaths occurred in the itraconazole group. The study suggests that itraconazole may be a promising treatment for systemic fungal infections in neutropenic patients, although further research is needed.
Paper Details　
Original Abstract of the Article :
Treatment of fungal infections in neutropenic patients continues to be a major problem for the clinician. Treatment of such infections with amphotericin B is difficult, because of its many side-effects. In a neutropenic mouse model, itraconazole appeared to be as effective as amphotericin B against ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000239049

データ提供：米国国立医学図書館（NLM）

Itraconazole: A New Hope for Neutropenic Patients with Fungal Infections?

The battle against fungal infections in neutropenic patients is a challenging one, often requiring aggressive treatment strategies. This research explores the potential of itraconazole as an alternative to amphotericin B, a conventional antifungal medication known for its significant side effects. The researchers aimed to evaluate the efficacy and safety of itraconazole in treating Candida and Aspergillus infections in neutropenic patients.

The study revealed that itraconazole demonstrated comparable efficacy to amphotericin B in treating Candida infections and even showed superior efficacy against Aspergillus infections in neutropenic patients. However, the researchers noted that itraconazole's absorption could be unreliable in seriously ill patients with impaired gastrointestinal function, suggesting a need for further investigation and careful monitoring.

A Potential Alternative to Amphotericin B for Fungal Infections

This study provides promising evidence for the potential of itraconazole as an alternative to amphotericin B in treating fungal infections in neutropenic patients. While further research is necessary to address the concerns regarding its absorption, the study's findings offer hope for a less toxic treatment option for this vulnerable population.

A New Weapon in the Arsenal Against Fungal Infections

Fungal infections pose a serious threat to the health of neutropenic patients. This study offers a glimmer of hope, suggesting that itraconazole could be a valuable addition to the arsenal against these infections. Further research and careful clinical management are crucial to ensure its safe and effective use in this challenging clinical setting.

Dr. Camel's Conclusion

Just as a desert tortoise can endure harsh conditions, neutropenic patients battling fungal infections require resilient treatment options. This study unveils the potential of itraconazole as a formidable weapon in this fight, offering a new beacon of hope in the quest for effective antifungal therapies.

Date :
  1. Date Completed 1992-07-30
  2. Date Revised 2018-02-16
Further Info :

Pubmed ID

1319311

DOI: Digital Object Identifier

10.1159/000239049

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.